Accepted Manuscript

Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317

Hirozumi Toyama, Shoko Sato, Hitoshi Shirakawa, Michio Komai, Yuichi Hashimoto, Shinya Fujii

PII:	S0960-894X(16)30143-3				
DOI:	http://dx.doi.org/10.1016/j.bmcl.2016.02.031				
Reference:	BMCL 23585				
To appear in:	Bioorganic & Medicinal Chemistry Letters				
Received Date:	22 January 2016				
Revised Date:	9 February 2016				
Accepted Date:	12 February 2016				



Please cite this article as: Toyama, H., Sato, S., Shirakawa, H., Komai, M., Hashimoto, Y., Fujii, S., Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: http://dx.doi.org/10.1016/j.bmcl.2016.02.031

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com

Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317

Hirozumi Toyama^a, Shoko Sato^b, Hitoshi Shirakawa^c, Michio Komai^c, Yuichi Hashimoto^a, Shinya Fujii^{a,*}

^a Institute of Molecular and Cellular Biosciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, 113-0032 Tokyo, Japan

^b Department of Biological Science and Technology, Tokyo University of Science, 6-3-1 Niijuku, Katsushika-ku, Tokyo 125-8585, Japan

^c Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Sendai 981-8555, Japan

ARTICLE INFO

Article history: Received

Revised

Accepted Available online

Keywords:

T0901317

Sila-substitution

Nuclear receptor

Pregnane X receptor (PXR)

Retinoic acid receptor-related orphan receptor (ROR)

Silanol

ABSTRACT

We report the design, synthesis, and physicochemical/biological evaluation of novel silanol derivative **6** (sila-T) as a silanol analog of multi-target nuclear receptor modulator T0901317 (**5**). Compound **6** showed intermediate hydrophobicity between the corresponding alcohol **13** and perfluoroalcohol **5**. While **5** exhibited potent activities toward liver X receptor α and β , farnesoid X receptor, pregnane X receptor (PXR) and retinoic acid receptor-related orphan receptor (ROR) γ , silanol **6** exhibited activity only toward PXR and RORs. Incorporation of silanol instead of perfluoroalcohol is a promising option for developing novel target-selective, biologically active compounds.

2009 Elsevier Ltd. All rights reserved.

The alcoholic hydroxy group is one of the most important functional groups in biologically active compounds.¹ It can be involved in hydrogen bonding and other polar contacts, functions as a nucleophilic reactive species, and markedly influences the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles of compounds. Physicochemical properties such as the acidity of the hydroxy group and the hydrophobicity of a neighboring group also affect the biological activity. For example, in nuclear receptor ligands such as vitamin D receptor (VDR) ligands,^{2,3} liver X receptor (LXR) ligands and pregnane X receptor (PXR) ligands,⁴ modification of the acidity or hydrophobicity of the tertiary alcohol therein significantly affects the biological activities. Therefore, the use of novel substitutes for the alcoholic hydroxy group is a promising approach for structural development of drug candidates.

One possible approach for exploiting novel isosteric structures of alcoholic hydroxy groups is utilization of heteroatom functionalities. In the case of acidic carboxy groups, application of several heteroatom-hydroxy functionalities, such as sulfonic acid, phosphonic acid, hydroxamic acid and boronic acid, has been intensively investigated in the field of medicinal chemistry.^{1,5} Regarding development of alternatives to the alcoholic hydroxy group, incorporation of heteroatoms is also useful, and silanol has potential as an isosteric substructure of alcoholic hydroxy groups.⁶⁻⁸ The silicon atom is isoelectronic with carbon, and therefore various silicon/carbon exchanges (sila-substitutions) of biologically active compounds have been investigated, particularly for optimization of hydrophobic moieties.⁹⁻¹⁶ There have also been some studies on the use of silanol as a hydrophilic structure. A representative example is a series of silanediol-based protease inhibitors, such as 1 and 2.¹⁷⁻¹⁹ Silanediols in these compounds function as mimics of the transition state in substrate hydrolysis. Another example is provided by cyclic silanol derivatives including sila-venlafaxine (3) and sila-haloperidol (4) (Figure 1).²⁰⁻²² In the case of sila-haloperidol, dehydration to afford the toxic pyridinium metabolite is blocked, because the Si=C double bond is intrinsically thermodynamically instable.²¹ Although other examples have also been reported, utilization of silanol in medicinal chemistry is still quite limited compared to other hydrophobic substructures.



Figure 1. Examples of silanol-based biologically active compounds.



Figure 2. Design scheme of the silanol analog of T0901317 (sila-T; **6**).

To expand the utility of silanols, we focused on the similarity between silanol and perfluoroalcohol. Perfluoroalcohols show higher acidity and hydrophobicity than the corresponding hydrocarbon-based alcohols, owing to the differences of electronegativity and molecular volume between alkyl groups and the corresponding perfluoroalkyl groups. Silanols also show somewhat higher acidity and hydrophobicity than the corresponding alcohols because of the differences of electronic properties and molecular volume between silanols and the alcohols.23 corresponding The 1,1,1,3,3,3-hexafluoro-2perfluoroalcoholic hydroxypropyl group, one of the functionalities, is a key structural motif of T0901317 (5), which is a benzenesulfonamide-based compound that exhibits agonistic activity toward multiple nuclear receptors, including LXRa and LXR β ,²⁴ PXR (also SXR; steroid and xenobiotic receptor),⁴ farnesoid X receptor (FXR),²⁶ and inverse agonistic activity toward retinoic acid receptor-related orphan receptors (RORs).² Previous researches revealed that the substituents around the hydroxy group have a significant influence on the activity and selectivity.^{4,28} So, we planned to investigate the activity profile of silanol 6 (named sila-T), a silanol analog of perfluoroalcoholbased T0901317 (5) (Figure 2).

Scheme 1 shows the synthesis of the designed silanol derivative **6**. Sulfonamide formation using 4-bromoaniline (**7**) and benzenesulfonyl chloride gave sulfonamide **8**, and then *N*-alkylation with 2,2,2-trifluoroethyl triflate afforded compound **9**. The bromo group of **9** was converted to dimethylsilanol using Denmark's conditions;²⁹ namely, in the presence of PdCl₂ and 2-(di-*tert*-butylphosphino)biphenyl (BPTBP), compound **9** reacted with 1,2-diethoxy-1,1,2,2-tetramethyldisilane to afford a ethoxydimethylsilyl derivative as an intermediate, and then removal of the ethyl group gave the desired silanol **6** (Scheme 1).

Table 1.

Determined and calculated physicochemical properties of compounds **5**, **6** and **13**.

	5	6	13
$\log P_{o/w}^{a}$	5.38	4.23	3.70
partial volume (PhXR ₂ OH) (Å ³) ^b	170.7	154.4	141.3
pK_a^{c}	7.5	12.5	14.6
^a Determined by HPLC method. ^{30 b} Cal	culated by	y MOPAC	software

(methods: PM3 EF)³¹. ^c Estimated by ACD/Chemsketch software³².

In order to investigate the structure-activity relationship, the corresponding alcohol derivative **13** was also synthesized as shown in Scheme 2. Reaction with ethyl 4-aminobenzoate (**10**) and benzenesulfonyl chloride gave sulfonamide **11**, which was *N*-alkylated to afford compound **12**. Treatment of compound **12** with methylmagnesium bromide gave the desired alcohol **13** (Scheme 2).

We next investigated the physicochemical properties of the compounds and T0901317 synthesized parent (5). Hydrophobicity was determined in terms of the octanol-water partition coefficient ($P_{o/w}$), using an HPLC method.³⁰ Silanol 6 exhibited a $\log P_{o/w}$ value of 4.23, which is larger than that of corresponding alcohol 13 ($logP_{o/w}$; 3.70). Previous results indicated that C/Si-exchange of alkylsilanes increases the hydrophobicity of the compounds by 0.5-0.7 in $\log P_{o/w}$ value,¹⁶ and the present result suggests that this is also the case with silanols. Compound 5 exhibited a $\log P_{o/w}$ value of 5.38, significantly larger than that of corresponding alcohol 13, and the hydrophobicity of silanol is intermediate between those of the alcohol and perfluoroalcohol. The difference of hydrophobicity can be mainly attributed to the difference of molecular volume, and the calculated values of partial volume of the compounds (PhXR₂OH) are consistent with the order of hydrophobicity. The acidity of the compounds was also calculated. The estimated pK_a value of compound 6 (12.5) is smaller than that of alcohol 13 (14.6), while both values are considerably larger than that of compound 5 (7.5). Though the acidity of silanols may be larger than that of corresponding alcohols, it is considerably smaller than that of perfluoroalcohols.



Scheme 1. Synthesis of silanol derivative 6 (sila-T). Reagents and conditions: (a) benzenesulfonyl chloride, pyridine, THF, rt, 93%; (b) NaH, CF₃CH₂OTf, DMF, 80°C, 68%; (c) i) PdCl₂, BPTBP, i-Pr₂EtN, (Me₂SiOEt)₂, NMP, 60°C; ii) AcOH, MeCN, Me₂N(CH₂)₂SH-HCl, 26%.



Scheme 2. Synthesis of alcohol derivative 13. Reagents and conditions: (a) benzenesulfonyl chloride, pyridine, THF, rt; (b) NaH, CF₃CH₂OTf, DMF, 80°C, 33% from 10; (c) MeMgBr, THF, 0°C, 77%.

Table 2.

Biological activities of compounds toward nuclear receptors.

iour aour :	ines of comp	sounds to nui	a maerear rece	Proibi					
compd	hL	XRα	hLXRβ		hFXR	hPXR	hRORα	hRORβ	hRORγ
	EC50 (µM)	$IC_{50} (\mu M)^{a}$	EC ₅₀ (µM)	$IC_{50} (\mu M)^{b}$	EC50 (µM)	EC50 (µM)	IC ₅₀	IC ₅₀ (µM)	IC ₅₀
							(µM)	-	(µM)
5	0.40	-	0.23	-	3.4	0.27	N.A.	N.A.	3.0
6	N.A.	N.A.	N.A.	N.A.	11 (23%) ^c	$0.88(61\%)^{d}$	53	60	43
13	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

^a Compounds were treated with 0.30 μ M T0901317 (5). ^b Compounds were treated with 0.10 μ M T0901317 (5). ^c Percentage with respect to the response to 10 μ M T0901317 (5). ^d Percentage with respect to the response to 1.0 μ M T0901317 (5). N.A.: No significant activity.

Next, the ligand potencies of the compounds toward hLXRa, hLXR β , hFXR, hPXR (SXR), and hROR α , β and γ were evaluated by means of luciferase reporter gene assay in HEK293 cells. Compound 5 exhibited significant agonistic activity toward LXR α and β , FXR and PXR, and inverse agonistic activity toward RORy.³³ On the other hand, compound 13 bearing a hydrocarbon-based alcohol instead of the perfluoroalcohol moiety of 5 exhibited no significant activity toward any of these nuclear receptors. These results indicate that high hydrophobicity and/or potent acidity of compound 5 is essential for biological activity toward these nuclear receptors. As for the silanol derivative 6, it exhibited neither agonistic nor antagonistic activity toward LXRs, and showed only modest partial agonistic activity toward FXR. In contrast to the case of LXRs and FXR, compound 6 exhibited inverse agonistic activity toward RORs. In addition, silanol 6 exhibited significant agonistic activity toward PXR. The PXR agonistic activity of silanol 6 is comparable to that of representative PXR agonist rifampicin (EC50 value for PXR; 1.1 µM, maximum efficacy is 75% compared to 5 in the same assay system). This result suggests that the silanol group could function as an isoster of the perfluoroalkyl group in the case of PXR ligands. The silanol functionality may be a useful option for development of other target-selective bioactive compounds.

X-Ray crystal structures of compound **5** complexed with $hLXR\alpha$, ³⁴ $hLXR\beta$, ³⁵ $hPXR^4$ and $hROR\gamma^{28}$ have been reported, and we conducted docking simulations using the crystal structures. ³⁶ In the co-crystal structures with ROR γ , the hexafluorohydroxypropyl group of compound **5** does not form a hydrogen bond to any amino acid residue of the receptor. In the docked structure with ROR γ , the hydroxy group of silanol **6** also shows no notable hydrogen bonding (Figure 3). These results suggest that hydrophobic interaction around the hydroxy moiety of the compound and the receptor surface of ROR γ is rather more important than polar interaction for the activity. It is possible that silanol **6** exhibited inverse agonistic activity towards RORs due to its relatively high hydrophobicity compared with that of the corresponding alcohol **13**.

In the cases of $LXR\alpha$, $LXR\beta$ and PXR, the hexafluorohydroxypropyl group of compound 5 forms a key hydrogen bond to a His residue of the receptor (His 421, His435 and His407, respectively). In the docked structure with PXR, the hydroxy group of silanol 6 also forms a hydrogen bond to His407. Structure-activity relationship study of T0901317 derivatives indicates that introduction of bulky hydrophobic substituents, as well as perfluoroalkyl groups, at the tertiary alcohol moiety is effective for potent PXR agonistic activity, whereas LXR agonistic activity strictly requires perfluoroalkyl substituents. We speculate that high hydrophobicity around the hydroxy moiety is important for PXR agonistic activity, whereas both hydrophobicity and high polarization of the hydroxy moiety may be essential for LXR agonistic activity. It is possible that silanol 6 exhibited PXR agonistic activity due to its relatively high hydrophobicity, but did not exhibit LXR ligand potency because of its lower polarization compared to compound 5, and

therefore shows selectivity for PXR over LXRs. Although the reason of the



Figure 3. Docking simulations of compound **6** using the crystal structures of hROR γ (PDB-ID: 4NB6, upper) and hPXR (PDB-ID: 2O9I, bottom). The protein surface is indicated as a light-blue mesh. The native ligand T0901317 (**5**) in the crystal structures is shown in green.

inactivity of compound **6** toward LXRs is unclear, alcohol/silanol exchange appears to be a promising option for modifying the activity profile of bioactive compounds.

In summary, in order to expand the utility of silanols in medicinal chemistry, we designed and synthesized silanol **6** (sila-T), a novel silanol derivative of T0901317 (**5**), focusing on the silanol functionality as an isosteric structure of perfluoroalcohol, and we compared the physicochemical properties and biological activities of **5** and **6**. In contrast to the parent compound **5**, which exhibited potent activities toward LXR α and β , FXR, PXR and ROR γ , the synthesized silanol **6** exhibited only agonistic activity toward PXR and inverse agonistic activity toward RORs. The difference in activity could be attributed to the similarity of

hydrophobicity and the difference of polarization between silanol and perfluoroalcohol. Silanol appears to be promising option for development of novel, target-selective, biologically active compounds. Further structural development and structure-activity relationship studies are in progress.

Acknowledgments

This work was partially supported by Platform for Drug Discovery, Informatics, and Structural Life Science, and Grants in-Aid for Scientific Research from The Ministry of Education, Culture, Sports, Science, and Technology, Japan, and the Japan Society for the Promotion of Science (KAKENHI Grant No. 26293025 (Y.H.), No. 25460146 (S.F.), Nos. 20380071 and 23380070 (H.S.)). We thank Dr. Shuichi Mori (Tokyo Medical and Dental University) for helpful discussions.

Supplementary Material

Supplementary data associated with this article can be found, in the online version.

References and notes

- 1. *The practice of medicinal chemistry*; Wermuth, C. G., Aldous, D., Raboisson, P., Rognan, D. Eds. Elsevier Academic Press, 2015, fourth ed..
- 2. *Vitamin D*; Feldman, D., Pike, J. W., Glorieux, F. H., Eds.; Elsevier Academic Press, 2005. second ed..
- 3. Sai, H.; Takatsuto, S.; Hara, N.; Ikekawa, N. *Chem. Pharm. Bull.* **1985**, *33*, 878.
- Xue, Y.; Chao, E.; Zuercher, W. J.; Willson, T. M.; Collins, J. L.; Redinbo, M. R. *Bioorg. Med. Chem.* **2007**, *15*, 2156.
- 5. Ballatore, C.; Huryn, D. M.; Smith, A. B. III *ChemMedChem* **2013**, *8*, 385.
- 6. Franz, A. K.; Wilson, S. O. J. Med. Chem. 2013, 56, 388.
- 7. Bains, W.; Tacke, R. Curr. Opin. Drug Discovery Dev. 2003, 6, 526.
- 8. Mills, J. S.; Showell, G. A. *Expert Opin. Invest. Drugs* 2004, 13, 1149.
- 9. Showell, G. A.; Mills, J. S. *Drug Discovery Today* **2003**, 8, 551.
- 10. Gately, S.; West, R. Drug Dev. Res. 2007, 68, 156.
- 11. Yamakawa, T.; Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, *K. J. Med. Chem.* **1990**, *33*, 1430.
- Tacke, R.; Müller, V.; Büttner, M. W.; Lippert, W. P.; Bertermann, R.; Daiß, J. O.: Khanwalkar, H.; Furst, A.; Gaudon, C.; Gronemeyer, H. *ChemMedChem* 2009, 4, 1797.
- Büttner, M. W.; Burschka, C., Daiss, J. O.; Ivanova, D.; Rochel, N.; Kammerer, S.; Peluso-Iltis, C.; Bindler, A.; Gaudon, C.; Germain, P.; Moras, D.; Gronemeyer, H.; Tacke, R. *ChemBioChem* 2007, *8*, 1688.
- Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Fleming, I.; Gaudon, C.; Ivanova, D.; Gronemeyer, H.; Tacke, R. *Organometallics* 2005, 24, 3192.
- Lippert, W. P., Burschka, C.; Götz, K.; Kaupp, M.; Ivanova, D.; Gaudon, C.; Sato, Y.; Antony, P.; Rochel, N.; Moras, D.; Gronemeyer, H.; Tacke, R. *ChemMedChem* 2009, 4, 1143.

- 16. Fujii, S.; Miyajima, Y.; Masuno. H.; Kagechika, H. *J. Med. Chem.* **2013**, *56*, 160.
- 17. Sieburth, S. McN.; Chen, C.-A. Eur. J. Org. Chem. 2006, 311.
- Sieburth, S. McN.; Nittoli, T.; Mutahi, A. M.; Guo, L. Angew. Chem., Int. Ed. 1998, 37, 812.
- Chen, C.-A.; Sieburth, S. McN.; Glekas, A.; Hewitt, G. W.; Trainor, G. L.; Erickson-Viitanen, S.; Garber, S. S.; Cordova, B.; Jeffry, S. Klabe, R. M. *Chem. Biol.* 2001, *8*, 1161.
- 20. Tacke, R.; Heinrich, T.; Bertermann, R.; Burschka, C.; Hamacher, A.; Kassack, M. U. *Organometallics* **2004**, 23, 4468.
- Tacke, R.; Popp, F.; Mueller, B.; Theis, B.; Burschka, C.; Hamacher, A.; Kassack, M. U.; Schepmann, D.; Wuensch, B.; Jurva, U.; Wellner, E. *ChemMedChem* 2008, 3, 152.
- Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Warneck, J. B. H.; Tacke, R. Organometallics 2006, 25, 1188.
- 23. Silicon in Organic, Organometallic, and Polymer Chemistry; Brook, M. A., John Wiley & Sons: New York, 2000.
- Schultz, J. R.; Tu, H.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Sham, B. *Genes Dev.* 2000, 14, 2831.
- 25. Mitro, N.; Vargas, L.; Romeo, R.; Koder, A.; Saez E. *FEBS lett.* **2007**, *581*, 1721.
- Houck, K. A.; Borchert, K. M.; Hepler, C. D.; Thomas, J. S.; Bramlett, K. S.; Michael, L. F.; Burris, T. P. *Mol. Genet. Metab.* 2004, *83*, 184.
- Kumar, N. Solt, L. A.; Conkright, J. J.; Wang, Y.; Istrate, M. A.; Busby, S. A.; Garcia-Ordonez, R. D.; Burris, T. P.; Griffin, P. R. *Mol. Pharmacol.* 2010, 77, 228.
- Fauber, B. P.; de Leon Boenig, G.; Burton, B.; Eidenschenk, C.; Everett, C.; Gobbi, A.; Hymowitz, S. G.; Johnson, A. R.; Liimatta, M.; Lockey, P.; Norman, M.; Ouyang, W.; René, O.; Wong, H. *Bioorg. Med. Chem. Lett.* 2013, 23, 6604.
- 29. Denmark, S. E.; Kallemeyn, J. M. Org. Lett. 2003, 5, 3483.
- 30. OECD Guideline for Testing of Chemicals 117, Partition Coefficient (n-octanol/water), High Performance Liquid Chromatography (HPLC) Method; March 1989.
- 31. http://openmopac.net/
- 32. ACD/chemsketch (Freeware) 2012, version 14.01, Advanced Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com, 2015.
- 33. Activities toward LXRs, FXR and RORs were evaluated using NR-LBD-GAL4 and MH100-luc. Activity toward hPXR was evaluated using VP16-hPXR and MDR1-luc.
- Svensson, S.; Oestberg, T.; Jacobsson, M.; Norstroem, C.; Stefansson, K.; Hallen, D.; Johansson, I. C.; Zachrisson, K.; Ogg, D.; Jendeberg, L. *EMBO J.* 2003, 22, 4625.
- Hoerer, S.; Schmid, A.; Heckel, A.; Budzinski, R.-M.; Nar, H. J. Mol. Biol. 2003, 334, 853.
- 36. Molecular docking was performed using AutoDock 4.2. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. J. Comput. Chem. 2009, 16, 2785. AutoDock parameters for silicon atom Rii = 4.30 and ɛii = 0.402 were used.

Click here to remove instruction text...

Graphical Abstract

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.

